SHORE Study Demonstrates HeartCare's Prognostic Value for Heart Transplant Recipients, Published in Journal of Heart and Lung Transplantation
CareDx (NASDAQ:CDNA) had its "hold (c-)" rating reaffirmed by analysts at
Weiss Ratings.
CareDx (NASDAQ:CDNA) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating.
CareDx to Participate in Upcoming Investor Conferences
CareDx (NASDAQ:CDNA) was upgraded by analysts at
Weiss Ratings from a "sell (d+)" rating to a "hold (c-)" rating.